Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASH 2025 | Exploring CD83 CARs as an approach to overcome CD19 antigen loss in B-cell malignancies

Marco Davila • 7 Dec 2025
ASH 2025
Acute Lymphoblastic Leukemia B-Cell Lymphoma Leukemia Lymphoma Non-Hodgkin Lymphoma CAR-T

Marco Davila, MD, PhD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, highlights the development of CD83-directed CAR T-cells as a strategy to overcome CD19 antigen loss in relapsed B-cell malignancies following CD19-targeted therapy. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Marco Davila

IL-2 mutein-mediated improvement of CAR-T function in R/R DLBCL
1:21
IL-2 mutein-mediated improvement of CAR-T function in R/R DLBCL
Marco Davila • 7 Dec 2025
CAR T-cell–driven induction of iNOS in TAMs promotes CAR T-cell resistance in B-cell lymphoma
1:21
CAR T-cell–driven induction of iNOS in TAMs promotes CAR T-cell resistance in B-cell lymphoma
Marco Davila • 7 Dec 2025
Correlation of serum inflammatory state and macrophage phenotype with CAR-T expansion and outcomes
1:33
Correlation of serum inflammatory state and macrophage phenotype with CAR-T expansion and outcomes
Marco Davila • 6 Dec 2024
A Phase I trial of ex vivo expanded donor gamma delta T-cells to prevent AML relapse after alloSCT
0:59
A Phase I trial of ex vivo expanded donor gamma delta T-cells to prevent AML relapse after alloSCT
Marco Davila • 6 Dec 2024

Related Videos

CARDINAL: Phase I study of TERN-701, an allosteric BCR-ABL1 inhibitor, in previously treated CML
2:19
CARDINAL: Phase I study of TERN-701, an allosteric BCR-ABL1 inhibitor, in previously treated CML
Marco Davila • 24 Nov 2025
VICEROY study: azacitidine, venetoclax, and gilteritinib in FLT3-mutated AML
3:31
VICEROY study: azacitidine, venetoclax, and gilteritinib in FLT3-mutated AML
Marco Davila • 8 Dec 2025
ALPHA3 study: first-line consolidation with cema-cel in MRD-positive LBCL after standard therapy
0:55
ALPHA3 study: first-line consolidation with cema-cel in MRD-positive LBCL after standard therapy
Marco Davila • 7 Dec 2025
Concurrent loss of TP53 and CDKN2A with tetraploidy predicts RT and poor prognosis in CLL
2:18
Concurrent loss of TP53 and CDKN2A with tetraploidy predicts RT and poor prognosis in CLL
Marco Davila • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals